Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DR26FCRG7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,532
Award facts
- Contract value 100% obligated
- $25,532.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $25,532.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count packages). This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 5, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical sourcing for Department of Defense healthcare operations.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V contract (SPE2DR) with a $500 million ceiling value and completion date of December 31, 2036, positioning the company as a critical regional pharmaceutical supplier for military healthcare facilities worldwide. The company's extensive product portfolio encompasses oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with this particular delivery order for Xtandi—a cancer treatment medication—reflecting the supplier's capability to meet the specialized pharmaceutical requirements of the federal military medical system. The contractor has demonstrated substantial federal contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FCRG7?
SPE2DR26FCRG7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FCRG7 worth?
The government has obligated $25,532 on SPE2DR26FCRG7.
Is contract SPE2DR26FCRG7 an order under another contract?
Yes. SPE2DR26FCRG7 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRG7 competed?
The extent of competition for SPE2DR26FCRG7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award